Last $57.36 USD
Change Today -0.49 / -0.85%
Volume 287.0K
ALNY On Other Exchanges
Symbol
Exchange
NASDAQ GS
Frankfurt
As of 8:10 PM 07/11/14 All times are local (Market data is delayed by at least 15 minutes).

Executive Profile*

Michael P. Mason

Principal Financial Officer, Principal Accounting Officer, Vice President of Finance and Treasurer, Alnylam Pharmaceuticals, Inc.
AgeTotal Calculated CompensationThis person is connected to 0 board members in 0 different organizations across 1 different industries.

39$500,850
As of Fiscal Year 2013

Background*

Mr. Michael P. Mason has been Principal Financial Officer, Principal Accounting Officer, Vice President of Finance and Treasurer at Alnylam Pharmaceuticals, Inc., since February 28, 2011. Mr. Mason served as Corporate Controller of Alnylam Pharmaceuticals, Inc., from December 2005 to February 2011 and also served as its Senior Director of Finance from August 2009 to February 2011 and as Director of Finance from June 2006 to July 2009. From May 2000 to November 2005, ...

Read Full Background

Corporate Headquarters*

300 Third Street
Cambridge, Massachusetts 02142

United States

Phone: 617-551-8200
Fax: 617-551-8101

Board Members Memberships*

There is no Board Members Memberships data available.

Education*

MBA
Babson College
Bachelor's Degree
Stetson University

Other Affiliations*

Annual Compensation*

Salary$252,144
Total Annual Compensation$252,144

Stock Options*

All Other Compensation$6,101
Exercised Options76,575
Exercised Options Value$1,503,479
Exercisable Options4,375
Unexercisable Options32,188
Total Value of Options$1,503,479
Total Number of Options118,138

Total Compensation*

Total Annual Cash Compensation$339,561
Total Short Term Compensation$252,144
Other Long Term Compensation$6,101
Total Calculated Compensation$500,850
*Data is at least as current as the most recent Definitive Proxy.
 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
ALNY:US $57.36 USD -0.49

COMPETITOR COMPENSATION

NamePosition/
Company
Compensation
Ali Mortazavi Chief Executive and Director
Silence Therapeutics plc
4.0K GBP
George W. Hebard III, M.B.AInterim Principal Executive Officer, Interim Chief Operating Officer and Secretary
Enzon Pharmaceuticals Inc.
$428.5K
Mark J. Ahn Ph.D.Chief Executive Officer, President and Director
Galena Biopharma, Inc.
$737.0K
Mark J. Murray Ph.D.Chief Executive Officer, President and Director
Tekmira Pharmaceuticals Corporation
$377.5K
Kleanthis G. Xanthopoulos Ph.D.Chief Executive Officer, President, Principal Financial & Accounting Officer and Director
Regulus Therapeutics Inc.
$600.0K
Compensation as of Fiscal Year 2012.

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact ALNYLAM PHARMACEUTICALS INC, please visit . Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.